Method for preventing and treating hearing loss using a neuturin protein product

• US 6,043,221 A
• Filed: 06/29/1998
• Issued: 03/28/2000
• Est. Priority Date: 07/30/1997
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Magal, Ella, Delaney, John M.
• Primary Examiner(s): DAVENPORT, AVIS MICHELLE
• Application Number:
  US09/106,486
• Time in Patent Office: 638 Days
• Field of Search: 514/12, 530/350, 530/324
• US Class Current: 514/8.4
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators

Abstract

The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.

Claims

1. A method for treating injury or degeneration of cells of the inner ear comprising administering to a subject a therapeutically effective amount of a neurturin protein product comprising an amino acid sequence set forth in SEQ ID NOs:

1, 2, 3, 4 or 5 wherein said neurturin protein product promotes the survival or function of cochlear hair cells and auditory neurons of the inner ear.

2. The method of claim 1, wherein the hearing loss is associated with injury or degeneration of neuroepithelial hair cells in the inner ear.

3. The method of claim 1, wherein the hearing loss is associated with injury or degeneration of spiral ganglion neurons.

4. The method of claim 1, wherein said auditory neurons are spiral ganglion neurons.

5. The method of claim 1, wherein the neurturin protein product has the amino acid sequence set forth in SEQ ID NO:

1.

6. The method of claim 1, wherein the neurturin protein product has the amino acid sequence set forth in SEQ ID NOs:

3 and 4.

7. The method of claim 1, wherein the neurturin protein product is (Met^-1)neurturin.

8. The method of claim 1, wherein the neurturin protein product is administered at a dose of about 1 μ

g/kg/day to about 100 mg/kg/day.

9. The method of claim 1, wherein the neurturin protein product is administered by cell therapy or gene therapy means wherein cells have been modified to produce and secrete the neurturin protein product.

10. The method of claim 8, wherein the cells have been modified ex vivo.

11. The method of claim 8, wherein the cells have been modified in vivo.